[Antabus syndrome under sulfonyl urea treatment].
D000079:Acetaldehyde / Q000097:blood; D001831:Body Temperature; D003371:Cough / Q000139:chemically induced; D003920:Diabetes Mellitus / Q000188:drug therapy; D004347:Drug Interactions; D004417:Dyspnea / Q000139:chemically induced; D000431:Ethanol / Q000009:adverse effects / Q000097:blood; D005145:Face; D006261:Headache / Q000139:chemically induced; D006805:Human Experimentation; D006801:Humans; D006940:Hyperemia / Q000139:chemically induced; D007773:Lactates / Q000097:blood; D011773:Pyruvates / Q000097:blood; D013453:Sulfonylurea Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D013577:Syndrome / Q000139:chemically induced; D013610:Tachycardia / Q000139:chemically induced; D013909:Thorax; D014839:Vomiting / Q000139:chemically induced
D007773:Lactates; D011773:Pyruvates; D013453:Sulfonylurea Compounds; D000431:Ethanol; D000079:Acetaldehyde
"Antabus-Syndrom" unter der Therapie mit Sulfonylharnstoffen.